Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28748504 | 0.84 | CHRNB1 (0.37) | ALDH1A1KMT2AMEN1CHRNA3CHRNB2 | |
| SCHEMBL7121435 | 0.78 | SMN1; SMN2 (0.52) | ALDH1A1KMT2AMEN1ATMCHRNA3 | |
| SCHEMBL7122500 | 0.77 | KMT2A (0.46) | ALDH1A1KMT2AMEN1ATMCHRNA3 | |
| SCHEMBL28994675 | 0.76 | CHRNA7 (0.49) | ALDH1A1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL31296350 | 0.74 | ROCK2 (0.52) | — | |
| SCHEMBL5088875 | 0.74 | HSD11B1 (0.59) | ALDH1A1KMT2A | |
| SCHEMBL30630153 | 0.72 | CHRNB2 (0.48) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL22229946 | 0.72 | CHRNB2 (0.48) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL7126821 | 0.71 | PSEN1 (0.45) | ALDH1A1CHRNA3TRPA1CHRNB2CHRNA4 | |
| SCHEMBL7118289 | 0.71 | CHRNA3 (0.50) | ALDH1A1KMT2ACHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664248-B2 | Well tolerated by animals, fish and plants | SYNGENTA INVESTMENT CORP. | 2003-12-16 | — | — | US | disclosed |
| US-20030166635-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | MAIENFISCH PETER (CH) | 2003-09-04 | — | — | US | disclosed |
| US-6506743-B2 | Especially for controlling insects. | SYNGENTA INVESTMENT CORPORATION | 2003-01-14 | — | — | US | disclosed |
| US-20020068733-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | MAIENFISCH PETER (CH) | 2002-06-06 | — | — | US | disclosed |
| US-6353001-B1 | PESTICIDES, INSECTICIDES, APHIDICIDES AND LARVICIDES | SYNGENTA INVESTMENT CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-0693066-B1 | 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-05-16 | — | — | EP | disclosed |
| US-6048824-A | 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | NOVARTIS CORPORATION (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0693066-A1 | NOVEL 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | Novartis AG (CH) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994024124-A1 | NOVEL 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068733-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | HCN1, HCN2, CNTN1 | ALDH1A1 1215/4885KMT2A 2135/4885MEN1 1527/4885 |
| US-20030166635-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | HCN1, HCN2, CNTN1 | ALDH1A1 1308/4885KMT2A 2316/4885MEN1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.